|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Systematic review and meta-analysis This trial is included in the following systematic reviews and meta-analyses: diabetes - anti hypertensive agent - type1 and 2 diabetic patients with hypertension Related trials ACCOMPLISH (diabetic subgroup), 2010 - benazepril + amlodipine vs benazepril + hydrochlorothiazide AVOID, 2008 - aliskiren vs placebo ALLHAT (lisi vs chlor, diabetic subgroup), 2002 - lisinopril vs chlorthalidone LIFE (diabetic subgroup), 2002 - losartan vs atenolol ALLHAT (amlodipine vs chlor, diabetic subgroup), 2002 - amlodipine vs chlorthalidone IPDM, 2001 - irbesartan vs placebo IDNT amlodipine, 2001 - amlodipine vs placebo RENAAL, 2001 - losartan vs placebo IDNT irbesartan, 2001 - Irbesartan vs placebo IDNT (irbesartan vs amlodipine), 2001 - Irbesartan vs amlodipine STOP-2 CCB (diabetic subgroup), 2000 - calcium-channel blocker vs diuretic or beta-blocker INSIGHT (diabetic subgroup), 2000 - Nifedipine vs coamilozide NORDIL (diabetic subgroup), 2000 - Diltiazem vs diuretic or beta-blocker STOP-2 (ACEI vs CCB) (diabetic subgroup), 2000 - ACE inhibitor vs CCB HOPE (diabetic subgroup), 2000 - ACE inhibitor vs placebo STOP-2 ACEI (diabetic subgroup), 2000 - ACE inhibitor vs diuretic or beta-blocker CAPP (diabetic subgroup), 1999 - captopril vs diuretic or beta-blocker Syst-Eur (diabetic subgroup), 1999 - nitrendipine vs placebo ABCD, 1998 - nisoldipine vs enalapril UKPDS 38, 1998 - captopril or atenolol vs control See also: |
Treatments
Patients
Method and design
Resultsn/N n/N cardiovascular event (fatal and non fatal) Cardiovascular death All cause death stroke (fatal and non fatal) myocardial infarction (fatal and non fatal)
Meta-analysis of all similar trials: anti hypertensive agent in diabetes for type1 and 2 diabetic patients with hypertension anti hypertensive agent in hypertension for diabetic patients Reference(s)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(c) 2004-2010 TrialResults-center - All Rights Reserved |